Overview
- 9 public-safe observations are available for this inspection.
- 8 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
8 Mar 2011
21 CFR 820.20(c)
Management review - defined interval, sufficient frequency
Cited by Roy C Stephens, Christine E Kelley
8 Mar 2011
21 CFR 820.22
Quality Audits - defined intervals
Cited by Roy C Stephens, Christine E Kelley
8 Mar 2011
21 CFR 820.30(f)
Design verification - output does not meet input requirement
Cited by Roy C Stephens, Christine E Kelley
8 Mar 2011
21 CFR 820.30(g)
Design Validation - Risk analysis not performed/inadequate
Cited by Roy C Stephens, Christine E Kelley
Inspected site
DGDiaPharma Group IncWest Chester, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 820.30(g) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 820.100(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 820.20(c) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 820.22 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 820.25(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 820.30(f) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 820.50 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 820.80(a) | Cited across public-safe Form 483 observations | 1x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 9 observations
The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere